Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States

INTRODUCTION: Our aim was to evaluate patient adherence and persistence with citrate-free adalimumab (ADA-CF), introduced in 2018 to reduce injection-site pain, compared with citrate-containing adalimumab (ADA-C). METHODS: This was a retrospective cohort study using a US claims database (IBM(®) Mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Martin, Patel, Pankaj, Chen, Naijun, Jing, Yonghua, Saffore, Christopher D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991045/
https://www.ncbi.nlm.nih.gov/pubmed/33222113
http://dx.doi.org/10.1007/s40744-020-00256-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991045/
https://www.ncbi.nlm.nih.gov/pubmed/33222113
http://dx.doi.org/10.1007/s40744-020-00256-x

Ejemplares similares